In intestinal cancer, the loss of the AhR enhances carcinogenesis in mouse models and treatment of wild-type mice with AhR agonists protects against chemical-induced and genetic models of colon cancer [42,43,44,45,46,47]. This evidence concerns the gene AHR and intestinal cancer.